Tuesday, August 25
TOPICS AND SPEAKERS:
Targeting the Cancer Mutanome
Emerging sequencing and bioinformatics technologies are now giving researchers new perspectives on the mutations in patient specific antigens,
now collectively known as the cancer mutanome. Our dinner short course offers academic and industry perspectives on the analytical and
computational methods used to identify neo-epitopes within a mutanome that are candidates for therapeutic intervention – and the potential
applications of this knowledge in patient diagnostics and immunotherapy. An open discussion format will allow those working in this space to share
insights and experiences on how to advance this new field into clinical practice.
Background and Update on Current Science
Course Leader: Laszlo Radvanyi, Ph.D., Chief Scientific Officer, Lion Biotechnologies
An overview on the emerging field of neo-antigen (mutanome) targeting will be presented. This overview will summarize the current approaches
used to deduce cancer neo-antigen epitopes for immunological targeting, specific examples of how neo-antigen targeting is being used
already in cancer immunotherapy, some of the obstacles being faced in the field, and the impact of neo-antigen targeting will have in the future
Neo-antigens in Cancer Immunotherapy
Lelia Delamarre, Ph.D., Scientist, Cancer Immunology, Genentech (Confirmed)
Tumors accumulate mutations, which can be recognized as foreign and induce immune responses. We developed a novel strategy to identify neoepitopes
by combining whole-exome sequencing and mass spectrometry analysis, along with structural prediction for discovery of immunogenic
antigens. This information can be used for the immuno-monitoring of cancer patients, and help identify which patients will benefit from
immunotherapy. Finally this knowledge could be exploited for the design of personalized vaccines.
Identifying Suitable Neoepitopes – Seeing Through the Fog of Suppression
Pramod Srivastava, M.D., Ph.D., Professor, Immunology and Medicine, University of Connecticut School of Medicine; Director, Carole and Ray
Neag Comprehensive Cancer Center (Confirmed)
Results of experiments, which do or do not eliminate the effect of immune suppression, while screening for immunogenic protective neoepitopes,
shall be presented and discussed.
What T Cells See on Human Cancer
Marit van Buuren, MSc, Ph.D. Student, Cancer Immunology, Netherlands Cancer Institute (Confirmed; Unpublished data)
Human tumors are characterized by large numbers of mutations, of which many hundreds can be contained within expressed genes, resulting in
so-called “neo-antigens”. The immune recognition of these antigens is hypothesized to be of significant importance to the activity of clinically used
immunotherapeutics in melanoma. With the use of in-house developed technologies to monitor T cell reactivity, we have shown that the T cell
recognition of neo-antigens is a common feature in human melanoma.
Thursday, August 27
Instructor: Ben Boyerinas, Ph.D., Scientist II, Cellular and Molecular Immunotherapy, bluebird bio
Adoptive cell therapy (ACT) is causing a great deal of excitement in the clinical research community due to its ability to utilize a patient’s own immune cells to effectively recognize and attack cancer cells. One well-studied modality of ACT employs genetically modified chimeric antigen receptor expressing T cells (CAR T) to target surface proteins overexpressed on cancer cells. This strategy is unique from other forms of ACT, as target recognition is not MHC restricted. CAR T cells have demonstrated significant clinical potency in the treatment of certain leukemias, and trials targeting solid tumor indications are now commencing.
This short course will address:
- History of CAR T development
- Strategies for effective gene delivery
- Cell production platforms and processes
- Initial clinical successes treating acute lymphoblastic leukemia
- Associated toxicities and clinical management
- Challenges associated with targeting solid tumor antigens
- The dilemma posed by the solid tumor microenvironment
- Novel CAR T designs and technologies
*Separate registration is required.